| Novel |
ABR
|
ABR activator of RhoGEF and GTPase |
- NRAGE signals death through JNK
- G alpha (12/13) signalling events
- RHOA GTPase cycle
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RAC3 GTPase cycle
|
|
|
| Novel |
CRK
|
CRK proto-oncogene, adaptor protein |
- ARMS-mediated activation
- ARMS-mediated activation
- Downstream signal transduction
- Regulation of actin dynamics for phagocytic cup formation
- p130Cas linkage to MAPK signaling for integrins
- VEGFA-VEGFR2 Pathway
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- MET activates RAP1 and RAC1
- MET receptor recycling
- Regulation of signaling by CBL
- FCGR3A-mediated phagocytosis
|
|
|
| Novel |
DIO3
|
iodothyronine deiodinase 3 |
- Regulation of thyroid hormone activity
|
|
|
| Novel |
EMP1
|
epithelial membrane protein 1 |
|
|
|
| Novel |
MRPL11
|
mitochondrial ribosomal protein L11 |
- Mitochondrial translation initiation
- Mitochondrial translation elongation
- Mitochondrial translation elongation
- Mitochondrial translation termination
- Mitochondrial ribosome-associated quality control
|
|
|
|
C1QA
|
complement C1q A chain |
- Initial triggering of complement
- Classical antibody-mediated complement activation
- Regulation of Complement cascade
|
- Cetuximab
- Etanercept
- Palivizumab
- Daclizumab
- Bevacizumab
|
- Classic complement pathway component defects, including the following eight diseases: C1q alpha-chain deficiency; C1q beta-chain deficiency; C1q gamma-chain deficiency; C1r deficiency; C1s deficiency; C2 deficiency; C3 deficiency; C4 deficiency
|
|
CDK13
|
cyclin dependent kinase 13 |
- TP53 Regulates Transcription of DNA Repair Genes
- Neutrophil degranulation
|
|
|
|
CEBPA
|
CCAAT enhancer binding protein alpha |
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of granulopoiesis
- Transcriptional regulation of granulopoiesis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
|
|
- Acute myeloid leukemia (AML)
|
|
COIL
|
coilin |
|
|
|
|
DUX4
|
double homeobox 4 |
- Zygotic genome activation (ZGA)
- Zygotic genome activation (ZGA)
|
|
|
|
EXOSC6
|
exosome component 6 |
- ATF4 activates genes in response to endoplasmic reticulum stress
- mRNA decay by 3' to 5' exoribonuclease
- Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
- Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
- KSRP (KHSRP) binds and destabilizes mRNA
- Major pathway of rRNA processing in the nucleolus and cytosol
- Nuclear RNA decay
|
|
|
|
FOXP1
|
forkhead box P1 |
|
|
|
|
GAB1
|
GRB2 associated binding protein 1 |
- PI3K Cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PIP3 activates AKT signaling
- GAB1 signalosome
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- RET signaling
- MET activates PTPN11
- MET activates RAP1 and RAC1
- MET receptor recycling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
|
|
|
|
GABRB1
|
gamma-aminobutyric acid type A receptor subunit beta1 |
- Signaling by ERBB4
- GABA receptor activation
- GABA receptor activation
|
- Lorazepam
- Ethchlorvynol
- Enflurane
- Temazepam
- Butabarbital
- Butalbital
- Phenytoin
- Etomidate
- Talbutal
- Pentobarbital
- Clobazam
- Meprobamate
- Eszopiclone
- Alprazolam
- Lindane
- Metharbital
- Chlordiazepoxide
- Amoxapine
- Adinazolam
- Lamotrigine
- Medroxyprogesterone acetate
- Clorazepic acid
- Midazolam
- Flurazepam
- Isoflurane
- Primidone
- Halazepam
- Propofol
- Diazepam
- Oxazepam
- Triazolam
- Ethanol
- Methoxyflurane
- Memantine
- Clonazepam
- Methyprylon
- Halothane
- Desflurane
- Flumazenil
- Estazolam
- Sevoflurane
- Glutethimide
- gamma-Hydroxybutyric acid
- Camazepam
- Delorazepam
- Flunitrazepam
- Ethyl loflazepate
- Cloxazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Ketazolam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
- Prasterone
- Taurine
- Ganaxolone
- Brotizolam
- Stiripentol
- Etizolam
- Thiocolchicoside
- Brexanolone
- Apalutamide
- Remimazolam
- 1,2-Benzodiazepine
- Pinazepam
- Medazepam
- Loprazolam
- Doxefazepam
- Lormetazepam
- Nordazepam
- Oxazepam acetate
- Cinazepam
- Bentazepam
- Mexazolam
|
|
|
HABP4
|
hyaluronan binding protein 4 |
|
|
|
|
HMGB1
|
high mobility group box 1 |
- ER-Phagosome pathway
- Apoptosis induced DNA fragmentation
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- TAK1-dependent IKK and NF-kappa-B activation
- MyD88 deficiency (TLR2/4)
- IRAK4 deficiency (TLR2/4)
- Pyroptosis
- Regulation of TLR by endogenous ligand
- Neutrophil degranulation
- Advanced glycosylation endproduct receptor signaling
- Advanced glycosylation endproduct receptor signaling
- TRAF6 mediated NF-kB activation
|
- Chloroquine
- Ethyl pyruvate
|
|
|
HMGB2
|
high mobility group box 2 |
- Apoptosis induced DNA fragmentation
|
|
|
|
HNRNPD
|
heterogeneous nuclear ribonucleoprotein D |
- mRNA Splicing - Major Pathway
- Processing of Capped Intron-Containing Pre-mRNA
|
|
|
|
HRK
|
harakiri, BCL2 interacting protein |
|
|
|
|
KLF1
|
KLF transcription factor 1 |
|
|
- Congenital dyserythropoietic anemias (CDAs)
|